Regarding the study of these cytokines, it is already known that both PACAP and lenalidomide have effects that lower the levels of these factors (IL-6 and TNF-α), thus attenuating the processes in the microenvironment that contribute to the survival of MM cells [23,92,93]. This evidence concerns the gene IL6 and Miyoshi myopathy.